GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through the GeneDx segment. The GeneDx segment primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. It provides carrier/variant-specific testing, targeted mosaic variant testing, and others.
Company codeWGS
Company nameGeneDx Holdings Corp
IPO dateSep 04, 2020
Founded at2020
CEOMs. Katherine A. Stueland
Number of employees1000
Security typeOrdinary Share
Fiscal year-endSep 04
Address333 Ludlow Street
CitySTAMFORD
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code06902
Phone18887291206
Websitehttps://sema4.com/
Company codeWGS
IPO dateSep 04, 2020
Founded at2020
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data